Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Terpos E et al. - In a review of the current evidence for use of bisphosphonates (BPs) in multiple myeloma (MM) and provide European Union-specific recommendations to support the clinical practice of treating myeloma bone disease, it appears that BPs are an essential component of MM therapy for minimizing skeletal morbidity. Recent retrospective data indicate that a modified dosing regimen and preventive measures can greatly reduce the incidence of osteonecrosis of the jaw (ONJ).

Methods

Results


Today in Myeloproliferative Dz...keeping you current

Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma
American Journal of Hematology, 11/10/09

An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Anticancer Research, 11/13/09

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Leukemia, 11/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address